TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03859505

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT
Description: The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated in a single session and they will receive a total dose of 0 J.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PBMT
Description: The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated in a single session and will receive a total dose of 220.05 J.
Study: NCT02467023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Biopsy Medication: Fentanyl
Description: Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and Urine Sampling
Description: Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood and Urine Sampling
Description: Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ineffective muscle stimulation
Description: An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.
Study: NCT02384395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Initial therapy for AHI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg
Description: Initial therapy for AHI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir 600 mg
Description: Initial therapy for AHI
Study: NCT03395756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot-Medroxyprogestereone Acetate
Description: Administration of 150 mg intramuscular depot medroxyprogesterone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot-Medroxyprogestereone Acetate
Description: Administration of 150 mg intramuscular depot medroxyprogesterone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot-Medroxyprogestereone Acetate
Description: Administration of 150 mg intramuscular depot medroxyprogesterone acetate
Study: NCT04693520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-801
Description: ALZ-801 265 mg twice daily (BID)
Study: NCT01285063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention: physical activity, dietary instructions and behavioral treatment.
Description: 3 months intervention. Nutritious plan: includes 6 meetings of the child and his or her parents with a dietician from the center.~Physical activity: physical trainings of 60 minutes each will be held twice a week.~behavioral treatment: all the participants will take part it a 45 minutes meeting of movement therapy once a week. The goal of such meeting is to strengthen nutritious and physical activity habits and to assimilate positive change in the participants' lifestyle.
Study: NCT04167514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin (AAT)
Description: AAT is a lyophilized product for intravenous administration
Study: NCT03768089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-121 suspension)
Description: Placebo matched to VX-121 suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-121 suspension)
Description: Placebo matched to VX-121 suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Suspension)
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study: NCT03331367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urine sample
Description: Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
Study: NCT03768089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study: NCT03331367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urine sample
Description: Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urine sample
Description: Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urine sample
Description: Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
Study: NCT02091492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
Study: NCT05547685

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Methylene blue intradermal injection
Description: Methylene blue intradermal injection
Study: NCT04007978

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Third generation CAR-T cells
Description: Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
Study: NCT00506480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial sampling
Description: Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial sampling
Description: Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
Study: NCT03768089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to TEZ/IVA)
Description: Placebo matched to TEZ/IVA for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to TEZ/IVA)
Description: Placebo matched to TEZ/IVA for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to IVA)
Description: Placebo matched to IVA for oral administration.
Study: NCT03830424

Intervention type: PROCEDURE
Intervention: Pain stimulus
Description: Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure

Intervention type: PROCEDURE
Intervention: Pain stimulus
Description: Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure

Intervention type: PROCEDURE
Intervention: Pain stimulus
Description: Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure

Intervention type: DIETARY_SUPPLEMENT
Intervention: Non-pharmacological pain relief
Description: Administration of sucrose/mother milk during pain stimulus
Study: NCT03768089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to IVA)
Description: Placebo matched to IVA for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Tablet)
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121 (Tablet)
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-121 tablet)
Description: Placebo matched to VX-121 tablet for oral administration.
Study: NCT04020471

Intervention type: OTHER
Intervention: Pain Scale/Medication Log
Description: Daily recording of pain level after surgery and recording of medication taken for pain relief.
Study: NCT05424965

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03830424

Intervention type: DIETARY_SUPPLEMENT
Intervention: Non-pharmacological pain relief
Description: Administration of sucrose/mother milk during pain stimulus
Study: NCT02100085

Intervention type: BIOLOGICAL
Intervention: GX-188E
Description: In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
Study: NCT00870792

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence report
Description: During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Adherence report
Description: During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
Study: NCT03522389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AOT with gait training
Description: AOT with gait training composes of program of watching video in different views of normal walk for 5 min.~After that, participants will receive gait training program. The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gait training
Description: To control a total time of training, the gait training group will watch video of Vincent van Gogh's painting for 5 min. After that, participants will training the gait as protocol of experimental group.~The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome.

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: There will be no intervention exercise program provide for the control group. They will receive education about dementia such as definition, etiology, sign and symptom, and caring.
Study: NCT01423305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol capsule.
Description: Oral administration with concomitant charcoal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol capsule for oral adm.
Description: Oral administration without concomitant charcoal.
Study: NCT02223897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huc-MSCs
Description: Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
Study: NCT03568734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal transplant
Description: At delivery, i.e. 39-40 weeks of gestation, the newborn infant is given 0.1 g maternal fecal sample (in 0.5 ml of the isotonic saline+10 % glycerol) dissolved in 10 ml of bank milk orally. The sample is given within 2 h of birth. Milk containing fecal sample (2 ml) is given as a part of a total feeding of 5-10 ml.
Study: NCT00694174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sucrose 24% oral solution
Description: sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile water
Description: sterile water 2 ml single dose to be administered orally one time prior to heel lance
Study: NCT00621153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan Cilexetil
Description: Candesartan Cilexetil 16 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Description: Candesartan Cilexetil 16 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan Cilexetil
Description: Candesartan Cilexetil 32 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Description: Candesartan Cilexetil 32 mg oral
Study: NCT00634374

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rx Medibottle
Description: Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
Study: NCT02099994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN
Description: intramuscular administration of Ad35-GRIN 5 x 10\^10 vp or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN
Description: intramuscular administration of Ad35-GRIN 5 x 10\^10 vp or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN
Description: intramuscular administration of Ad35-GRIN 5 x 10\^10 vp or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv
Description: IM administration of MVA.HIVconsv 2 x 10\^8 pfu or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv
Description: IM administration of MVA.HIVconsv 2 x 10\^8 pfu or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv
Description: IM administration of MVA.HIVconsv 2 x 10\^8 pfu or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pSG2.HIVconsv DNA
Description: IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Electroporated pSG2.HIVconsv
Description: IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
Study: NCT01411202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: One time injection of normal saline (placebo) into Pleurx catheter
Study: NCT01480050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: standard of care drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine
Description: tracer used for FLT PET CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibefradil
Study: NCT03261973

Intervention type: DEVICE
Group type: OTHER
Intervention: DV8
Description: DV8 esophageal deviation tool
Study: NCT02288052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing program
Description: 6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretch & Relaxation program
Description: 6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.